CMS has announced that the Oncology Care Model (OCM) developed by the Center for Medicare and Medicaid Innovation has 196 practices and 17 payers enrolled for participation.
The Oncology Care Model (OCM) developed by the Center for Medicare and Medicaid Innovation (CMMI) has 196 practices and 17 payers enrolled for participation, CMS announced earlier today. The OCM, a 5-year model that begins on July 1, 2016, and runs through June 30, 2021, is focused on providing better, more coordinated care.
The OCM is a value-based model that includes financial and performance accountability for episodes of care for chemotherapy administration in patients with cancer, with the objective of improving care while lowering costs. Shared decision-making with patients is encouraged under the OCM, and physicians are provided an incentive to comprehensively address the complex care needs of patients receiving chemotherapy, while improving outcomes.
Participation of commercial payers is an added incentive for practices to participate in the model. Aligned financial incentives among commercial health plans and CMS will help the model reach a much broader population of patients. Additionally, payers will have the flexibility to design their own payment incentives for providers while aligning with CMMIs goals of care.
With a 6-month episode that begins with chemotherapy, participating practices are expected to:
The 2 part payment system under OCM includes a per-beneficiary Monthly Enhanced Oncology Service payment for the duration of the episode, which is set at $160. There is also the potential for a performance-based payment for episodes of chemotherapy care, an incentive to lower total costs and improve care rendered during a defined episode.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More